The FDA approves a new diagnostic tool enhancing precision treatment for advanced endometrial carcinoma, improving patient ...

The most common adverse events reported in the neoadjuvant and adjuvant pembrolizumab plus enfortumab vedotin arm were pruritus, alopecia, diarrhea, fatigue and anemia. No new safety signals were ...

Keytruda showed a significant survival benefit over Tecentriq and Opdivo in older adults with metastatic NSCLC, with a 33% ...

The findings showed that disease progression not only worsens patient outcomes but also significantly increases overall healthcare costs. Late-stage disease and post-recurrence cystectomy were ...

Topline data from Phase 3 (IOB-013) clinical trial in advanced melanoma presented at ESMO; data highlights improvements in PFS achieved in overall population and across virtually all subgroups, althou ...

Low-dose pembrolizumab increased complete pathological response when added to dose-dense taxane backbone in patients with stage II to III triple-negative breast cancer,” said Atul Batra, MD.

AEMD READ THE FULL AEMD RESEARCH REPORT Cohort 2 recruitment has begun following positive data from Cohort 1 Aethlon Medical (NASDAQ:AEMD) announced FY 2Q (quarter ended September 30, 2025) results ...

HCW Biologics Inc. (the 'Company” or 'HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on ...

Announced Encouraging Data on both NUC-7738 and NUC-3373 Initial Data from the Expansion Study of NUC-7738 Expected in Q4 2025 with Final Data ...

HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing ...

Company Announced Completion of VERSATILE-002 Phase 2 trial of PDS0101 + Pembrolizumab in HPV16-Positive Recurrent/Metastatic Head and Neck ...

The KEYMAKER-U03 trial showed a triplet regimen of belzutifan, pembrolizumab, and lenvatinib significantly improved ...